KR102777452B1 - N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 - Google Patents

N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 Download PDF

Info

Publication number
KR102777452B1
KR102777452B1 KR1020247022172A KR20247022172A KR102777452B1 KR 102777452 B1 KR102777452 B1 KR 102777452B1 KR 1020247022172 A KR1020247022172 A KR 1020247022172A KR 20247022172 A KR20247022172 A KR 20247022172A KR 102777452 B1 KR102777452 B1 KR 102777452B1
Authority
KR
South Korea
Prior art keywords
compound
crystalline form
crystalline
certain embodiments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247022172A
Other languages
English (en)
Korean (ko)
Other versions
KR20240108581A (ko
Inventor
제이콥 피. 사이즈모어
리팅 구오
마흐무드 미르메흐라비
예칭 쑤
Original Assignee
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64734113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102777452(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아지오스 파마슈티컬스 아이엔씨. filed Critical 아지오스 파마슈티컬스 아이엔씨.
Priority to KR1020257007025A priority Critical patent/KR20250034202A/ko
Publication of KR20240108581A publication Critical patent/KR20240108581A/ko
Application granted granted Critical
Publication of KR102777452B1 publication Critical patent/KR102777452B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247022172A 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 Active KR102777452B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257007025A KR20250034202A (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US62/589,822 2017-11-22
US201862691709P 2018-06-29 2018-06-29
US62/691,709 2018-06-29
KR1020207015018A KR102682430B1 (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015018A Division KR102682430B1 (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257007025A Division KR20250034202A (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태

Publications (2)

Publication Number Publication Date
KR20240108581A KR20240108581A (ko) 2024-07-09
KR102777452B1 true KR102777452B1 (ko) 2025-03-10

Family

ID=64734113

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247022172A Active KR102777452B1 (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
KR1020207015018A Active KR102682430B1 (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
KR1020257007025A Pending KR20250034202A (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207015018A Active KR102682430B1 (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
KR1020257007025A Pending KR20250034202A (ko) 2017-11-22 2018-11-21 N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태

Country Status (27)

Country Link
US (2) US11254652B2 (https=)
EP (2) EP3713919B1 (https=)
JP (2) JP7275130B2 (https=)
KR (3) KR102777452B1 (https=)
CN (2) CN117551030A (https=)
AU (2) AU2018373122B2 (https=)
BR (1) BR112020010185A2 (https=)
CA (1) CA3081945A1 (https=)
DK (1) DK3713919T3 (https=)
ES (1) ES2959764T3 (https=)
FI (1) FI3713919T3 (https=)
HR (1) HRP20230931T1 (https=)
HU (1) HUE063264T2 (https=)
IL (3) IL274488B2 (https=)
LT (1) LT3713919T (https=)
MD (1) MD3713919T2 (https=)
MX (2) MX2020005348A (https=)
PH (1) PH12020550644A1 (https=)
PL (1) PL3713919T3 (https=)
PT (1) PT3713919T (https=)
RS (1) RS64592B1 (https=)
SG (1) SG11202004587XA (https=)
SI (1) SI3713919T1 (https=)
SM (1) SMT202300327T1 (https=)
TW (1) TWI808108B (https=)
UA (1) UA127502C2 (https=)
WO (1) WO2019104134A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598337B (zh) * 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020237047A1 (en) * 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
WO2021154987A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mitapivat and process for preparation thereof
CN116568281A (zh) * 2020-09-25 2023-08-08 安吉奥斯医药品有限公司 药物制剂
EP4216956A1 (en) * 2020-09-25 2023-08-02 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023154036A1 (en) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
EP4329758A1 (en) * 2021-04-30 2024-03-06 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
IL312679A (en) 2021-11-16 2024-07-01 Agios Pharmaceuticals Inc Compounds for the treatment of anemia associated with MDS and other conditions
WO2024084501A1 (en) 2022-10-17 2024-04-25 Mylan Laboratories Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos
WO2024228131A1 (en) * 2023-05-02 2024-11-07 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof
WO2025008787A1 (en) * 2023-07-05 2025-01-09 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of mitapivat hemisulfate
WO2025083627A1 (en) * 2023-10-18 2025-04-24 Apitoria Pharma Private Limited Novel crystalline forms of mitapivat sulfate and processes for preparation
WO2025146636A1 (en) * 2024-01-03 2025-07-10 Tianish Laboratories Private Limited Novel crystalline polymorphs of mitapivat sulfate salt

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056153A1 (en) 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722662B2 (en) 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
IN191496B (https=) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
US20020055495A1 (en) 2000-09-05 2002-05-09 Anthony Jannetta Two-component anti-emetic composition
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
CN101711164B (zh) 2007-01-18 2014-06-04 密苏里-哥伦比亚大学 可修复肌纤维膜中的神经元型一氧化氮合酶的合成小/微-抗肌萎缩蛋白基因
TWI598337B (zh) * 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
AU2011283008A1 (en) 2010-07-30 2013-01-24 Merck Sharp & Dohme Corp. Inhibition of CYP3A drug metabolism
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015225496A1 (en) 2014-03-03 2016-10-13 Sujata ACHARJEE Chimeric dystrophin-VSV-G-protein to treat dystrophinopathies
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056153A1 (en) 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Also Published As

Publication number Publication date
IL322576A (en) 2025-10-01
IL274488A (en) 2020-06-30
US11254652B2 (en) 2022-02-22
KR20200090787A (ko) 2020-07-29
TW201930289A (zh) 2019-08-01
CN117551030A (zh) 2024-02-13
EP3713919B1 (en) 2023-08-02
IL305343B1 (en) 2025-09-01
AU2018373122B2 (en) 2023-11-09
HRP20230931T1 (hr) 2023-11-24
JP7275130B2 (ja) 2023-05-17
US12612381B2 (en) 2026-04-28
EP3713919A1 (en) 2020-09-30
SI3713919T1 (sl) 2023-10-30
UA127502C2 (uk) 2023-09-13
IL274488B2 (en) 2024-01-01
KR102682430B1 (ko) 2024-07-08
IL305343A (en) 2023-10-01
MX2020005348A (es) 2020-08-13
FI3713919T3 (fi) 2023-09-29
EP4285904A2 (en) 2023-12-06
MD3713919T2 (ro) 2024-02-29
LT3713919T (lt) 2023-10-10
MX2022009998A (es) 2022-09-19
AU2024200724A1 (en) 2024-02-22
TW202334115A (zh) 2023-09-01
PH12020550644A1 (en) 2021-04-26
CN111372920A (zh) 2020-07-03
CA3081945A1 (en) 2019-05-31
PT3713919T (pt) 2023-10-26
IL274488B1 (en) 2023-09-01
KR20250034202A (ko) 2025-03-10
ES2959764T3 (es) 2024-02-28
US20220220093A1 (en) 2022-07-14
HUE063264T2 (hu) 2024-01-28
WO2019104134A1 (en) 2019-05-31
EP4285904A3 (en) 2023-12-20
IL305343B2 (en) 2026-01-01
JP2021504338A (ja) 2021-02-15
BR112020010185A2 (pt) 2021-01-12
AU2018373122A1 (en) 2020-05-21
AU2024200724B2 (en) 2026-02-05
DK3713919T3 (da) 2023-09-25
PL3713919T3 (pl) 2023-12-27
CN111372920B (zh) 2023-10-20
SG11202004587XA (en) 2020-06-29
SMT202300327T1 (it) 2023-11-13
US20200277279A1 (en) 2020-09-03
RS64592B1 (sr) 2023-10-31
TWI808108B (zh) 2023-07-11
JP2023093762A (ja) 2023-07-04
KR20240108581A (ko) 2024-07-09

Similar Documents

Publication Publication Date Title
KR102777452B1 (ko) N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
US20230192618A1 (en) Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
HK40104405A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
EA042666B1 (ru) Кристаллические формы n-(4-(4-(циклопропилметил)пиперазин-1-карбонил)фенил)хинолин-8-сульфонамида
TWI922809B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
EP4114835A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240702

Application number text: 1020207015018

Filing date: 20200526

PA0201 Request for examination
PG1501 Laying open of application
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240921

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241129

PG1601 Publication of registration